|
May 2
|
Novo Nordisk Lifts Full-Year Sales Outlook as Obesity, Diabetes Drugs Drive First-Quarter Topline Beat
|
|
May 2
|
UPDATE 1-Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1
|
|
May 2
|
Why Markets Must Beware Powell’s Comments on Fed Rate Hikes, and 5 Other Things to Know Today
|
|
May 2
|
Growing demand for weight loss treatments drives sales at drugmaker Novo Nordisk
|
|
May 2
|
Trending tickers: Shell, Apple, Novo Nordisk and Standard Chartered
|
|
May 2
|
UPDATE 7-Novo Nordisk trims price for blockbuster obesity drug as competition heats up
|
|
May 2
|
Novo Nordisk trims price for blockbuster obesity drug as competition heats up
|
|
May 2
|
Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024
|
|
May 2
|
FOCUS-British pharmacies vie for weight-loss patients with drug price cuts
|
|
May 1
|
Dow Jones Futures: Stock Market Erases Fed Gains; Carvana Skyrockets Late
|
|
May 1
|
Apple, Novo Nordisk earnings, jobless claims: What to watch
|
|
May 1
|
Breakouts In Focus: Google Goes Wild As Tasty IPO Sets Up
|
|
May 1
|
Danish Medicines Agency Says Type 2 Diabetes Patients Should Start Treatment With 'Cheaper' Drugs
|
|
May 1
|
UPDATE 1-Novo Nordisk owner to invest $200 million in quantum computing startups
|
|
May 1
|
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
|
|
May 1
|
Novo Nordisk owner to invest $200 million in quantum computing startups
|
|
Apr 30
|
IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
|
|
Apr 30
|
Ozempic Maker Novo Nordisk Has Denmark’s Economy Hooked
|
|
Apr 30
|
Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications
|
|
Apr 30
|
Eli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
|